Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-05
1998-12-15
Prouty, Rebecca E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 13, 514 17, 530324, 530325, 530350, 435694, 4352523, 4353201, 435 696, 435 698, A61K 3800, C07K 100, C12P 2106, C12N 120
Patent
active
058497021
ABSTRACT:
The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (von Willebrand Factor) GP1b binding domain. These polypeptides, may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides, to inhibit platelet aggregation.
REFERENCES:
patent: 4620948 (1986-11-01), Builder et al.
patent: 4666884 (1987-05-01), Hawiger et al.
patent: 5200510 (1993-04-01), Kumar et al.
patent: 5238919 (1993-08-01), Zimmerman et al.
patent: 5321127 (1994-06-01), Handin
patent: 5340727 (1994-08-01), Ruggeri et al.
patent: 5344783 (1994-09-01), Scarborough et al.
Sadler, et al., PNAS USA 82: 6394-6398 (Oct. 1985).
Girma, et al., Blood, 67: 1356-1366, (May 1986).
Houdijk, et al. "Thrombosis and Haemostasis", 56:(3): 391-396 (Sep. 1986).
Mohri, et al., J. Biological Chemistry, 264 (29): 17361-17367, (Oct. 1989).
Sixma, et al., J. Clinical Investigations 74: 736-744, (Sep. 1984).
Pietu, et al., Biochem. Biophys. Res. Comm. 164: 1339-1347 (Nov. 1989).
Fujimura, et al., J. Biol. Chem. 261: 381-385 (Jan. 1986).
Mohri, et al., J. Biol. Chem. 263: 17901-17904 (Dec. 1988).
Sugimoto, et al., Abstract No. 2371 in Supplement to Circulation, 82: p. III-597 (Oct. 1990).
Andrews, et al., Biochemistry, 28: 8326/8336, (1989).
Sadler et al., Abstract No. 3950 in Federation Proceedings, vol. 44, No. 4, p. 1069 (March 1985).
Lynch et al., Cell, vol. 41, pp. 49-56 (May 1985).
Ginsburg et al., Science, vol. 228, pp. 1401-1406 (Jun. 1985).
Verweij et al., Nucleic Acids Research, vol. 13, No. 13, pp. 4699-4717 (Jul. 1985).
Prior et al., Bio/Technology, vol. 10, pp. 66-73 (Jan. 1992).
Fujimura et al., Abstract No. 1222 in Blood, vol. 66, p. 334a (Nov. 1985).
Gralnick et al., Proc. Nalt. Acad. Sci., vol. 89, pp. 7880-7884 (1992).
Wick et al., J. Clin. Invest., vol. 80, pp. 905-910 (1987).
Peterson et al., Blood, vol. 69, pp. 625-628 (1987).
Yammamoto et al., Thrumbosis Res., vol. 39, pp. 751-759 (1985).
Harmon et al., Bio Chemistry, vol. 27, pp. 2151-2157 (1988).
Pareti et al., J. Biol. Chem. 261(32):15310-15315 (1986) (Exhibit 4).
Fujimura et al., J. Biol. Chem. 262(4):1734-1739 (1987) (Exhibit 5).
Grossi et al., FASEB J. 2(8):2385-2395 (1988) (Exhibit 6).
Mohri et al., CA114:182561m (1990) (Exhibit 7).
Mancuso et al., J. Biol. Chem. 264(33):19514-19527 (1989) (Exhibit 8).
Carruthers et al., Biochemistry 28:8337-8346 (1989) (Exhibit 9).
Fuster et al., Circulation Res. 51:587-593 (1982) (Exhibit 10).
Kitigawa et al., Cancer res. 49:537-541 (1989) (Exhibit 11).
Karpatkin et al., J. Clin. Invest. 81(4):1012-1019 (1988) (Exhibit 12).
McBride et al., The New England Journal of Medicine 318(26):1734-1737 (1988) (Exhibit 13).
Bellinger et al., P.N.A.S. 84:8100-8104 (1987) (Exhibit 14).
Pieto, et al "Production of E. coli of a Biologically Active Subfragment of vWF corresponding to platelet glycoprotein Ib collagen & heparin Binding domains", Biochemical & Biophysical Research Communication, (1989), vol. 164, No. 3; 1339-1347.
Yamamoto, et al "Monoclonal Ab to Glycoprotein Ib inhibits both Thrombin & restocetin-induced platelet aggregations", Thrombosis Res. 39, 751-759, 1985.
Harmon, et al "Platelet Activation by Thrombin in the absence of the High Affinity Thrombin Receptor", Biochemistry 1988, 27, 2151-2157.
Wick, et al "Unusally Large vWF Multimers Increase Adhesion of Sickle erythrocytes to Human Endothelial Cells under Controlled Flow" J. Clinical Invest. 1987, 80, 905-910.
Peterson, et al, Shear induced platelet aggreagation requires vWF & platelet membrane glycoprotein Ib & IIb-IIa., Blood 1987, 69; Abstract.
Gralnick, et al, Ammomeric vWF fragment, Lee 504-Ser 728 inhibits vWF interaction w/glycoprotein Ib-Ik, Proc. Natl. Acad. Sci, 1992, 89; 7880-7884.
Garfinkel Leonard
Richter Tamar
Bio-Technology General Corp.
Prouty Rebecca E.
Saidha Tekchand
White John P.
LandOfFree
Cloning and production of human von Willebrand factor GPIB bindi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning and production of human von Willebrand factor GPIB bindi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning and production of human von Willebrand factor GPIB bindi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1457919